/
Other
Treatment
306
Pipeline Programs↗
297
Active Trials↗
232
Companies Involved↗
Treatment is a highly competitive landscape with 306 programs across 232 companies. The most active players are OriCell Therapeutics Co., Ltd., BioMarin Pharmaceutical, Argenx. 63 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical116
Phase 115
Phase 363
Approved
No programs
Analysis
Modality Breakdown
85%
Small molecule
246 of 288 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 288 classified programs, each share of the total. Modality classified for 100% of 306 pipeline programs.
Analysis
Trial Status
2,786
clinical trials
Completed1,655 · 59%
Unknown status436 · 16%
Terminated246 · 9%
Recruiting167 · 6%
Withdrawn102 · 4%
Active, not recruiting71 · 3%
Other109 · 4%
Clinical Trials
Trial Activity
2786 trials
Anlotinib Capsules in the Treatment for IPF/PF-ILDs
Recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2/3·NCT05828953·30 enrolled
Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
Recruiting·—·Phase 1·NCT04500847·35 enrolled
Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB
Recruiting·—·Phase 4·NCT07478484·144 enrolled
Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity
Recruiting·—·Phase 4·NCT03935984·37 enrolled
Page 1 of 186
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)